Brind.
  1. Ensysce Biosciences is developing novel opioid candidates, including PF614, aimed at treating pain and addressing the opioid addiction epidemic.

Cy Biopharma transaction adds clinical-stage pain therapy to its portfolio, involving Ensysce Biosciences.

1 report, 1 independent Updated Aug 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Cy Biopharma transaction adds clinical-stage pain therapy to its portfolio, involving Ensysce Biosciences.

Keep exploring

Part of

Ensysce Biosciences is developing novel opioid candidates, including PF614, aimed at treating pain and addressing the opioid addiction epidemic. All 2 developments

Coverage

Newest first; wire copies grouped